Holen Sie sich die Stockscreener-App
460.87
0.92%
4.18
Handel nachbörslich:
482.46
21.59
+4.68%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt VRTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$456.69
Offen:
$455.59
24-Stunden-Volumen:
1.16M
Relative Volume:
0.82
Marktkapitalisierung:
$117.08B
Einnahmen:
$12.07B
Nettoeinkommen (Verlust:
$3.95B
KGV:
30.05
EPS:
15.3349
Netto-Cashflow:
$3.19B
1W Leistung:
-5.18%
1M Leistung:
-2.12%
6M Leistung:
+16.24%
1J Leistung:
-5.62%
1-Tages-Spanne:
$450.78
$461.26
1-Wochen-Bereich:
$450.67
$484.10
52-Wochen-Spanne:
$362.50
$519.68
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Firmenname
Vertex Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 341-6393
Adresse
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
460.87 | 116.01B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.60 | 80.33B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
740.40 | 44.42B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.59 | 42.53B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
302.29 | 33.32B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-13 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2026-01-06 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-09-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Eingeleitet | Raymond James | Mkt Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-19 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-02-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Herabstufung | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-05-04 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-01-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-05-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Bestätigt | JP Morgan | Overweight |
| 2022-01-27 | Bestätigt | Morgan Stanley | Underweight |
| 2022-01-27 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Hold |
| 2022-01-27 | Bestätigt | Wolfe Research | Outperform |
| 2022-01-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-30 | Eingeleitet | Daiwa Securities | Outperform |
| 2020-11-30 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Eingeleitet | Bernstein | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-07-31 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-09-03 | Hochstufung | Goldman | Neutral → Buy |
| 2019-08-01 | Herabstufung | Needham | Buy → Hold |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | In-line |
| 2019-03-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
Vertex Stock Pre-Market (+4.7%): Positive Phase 3 Kidney Drug Data - Trefis
Vertex’s kidney disease drug meets main goal in late-stage trial - WNWN-FM
Vertex Pharmaceuticals (VRTX) Surges 7% Following Promising Tria - GuruFocus
Wolfe Research reiterates Vertex stock rating on IgAN trial data - Investing.com
Vertex Pops On 'Remarkable' Late-Stage Results - Investor's Business Daily
Vertex kidney disease drug hits mark in late-stage study - BioPharma Dive
Vertex says its drug successfully reduced marker of kidney disease in late-stage trial - statnews.com
Vertex jumps after positive Phase 3 interim data for povetacicept in IgA nephropathy - Quiver Quantitative
Vertex Rises After Kidney Drug Meets Goal in Late-Stage Trial - Bloomberg
Vertex Pharmaceuticals (VRTX) Reports Positive Phase 3 Trial Res - GuruFocus
After-hours movers: Hewlett Packard Enterprise, Yext, Vertex Pharma By Investing.com - Investing.com Canada
After-hours movers: Hewlett Packard Enterprise, Yext, Vertex Pharma - Investing.com
Vertex Pharmaceuticals Stock Jumps After The Close: Here's Why - Benzinga
Vertex's kidney disease drug meets main goal in late-stage trial - AOL.com
Vertex to seek US approval after promising late-stage results for kidney drug - Reuters
Is A Vertex Buyout Of Crispr Therapeutics Inevitable? Here's My Take (NASDAQ:CRSP) - Seeking Alpha
Experimental kidney drug slashes protein in urine in major Vertex trial - Stock Titan
Buying This 1 Biotech Stock Now Could Help Make You a Multimillionaire Retiree - The Motley Fool
Prevail Innovative Wealth Advisors Boosts Vertex Pharmaceuticals Stake - National Today
2,440 Shares in Vertex Pharmaceuticals Incorporated $VRTX Purchased by Legacy Capital Group California Inc. - MarketBeat
Neo Ivy Capital Management Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Cresset Asset Management LLC Decreases Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Insider Sell: Duncan Mckechnie Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex presents new Phase IV data on Journavx - The Pharma Letter
Quantbot Technologies LP Buys $1.46M Stake in Vertex Pharmaceuticals - National Today
Quantbot Technologies LP Takes $1.46 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Dimensional Fund Advisors Increases Vertex Pharmaceuticals Stake - National Today
Dimensional Fund Advisors LP Purchases 187,359 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex to Participate in Upcoming March Investor Conferences - Business Wire
Vertex Pharmaceuticals to Present Data on JOURNAVX® for Pain Management After Aesthetic and Reconstructive Surgeries - geneonline.com
Did Vertex’s (VRTX) Earnings Beat and Advancing Pipeline Just Shift Its Investment Narrative? - Yahoo Finance
Vertex Pharmaceuticals Incorporated Presents New Data on JOURNAVX for Effective Pain Management Following Aesthetic and Reconstructive Procedures - marketscreener.com
Vertex Pharmaceuticals (VRTX) Reports Positive Phase 4 Study Res - GuruFocus
That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures - Business Wire
2 Biotech Giants to Buy in 2026 - AOL.com
South Dakota Investment Council Cuts Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
2 Biotech Giants to Buy in 2026 - The Motley Fool
CI Investments Inc. Trims Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Hits Day High with Strong 3.48% Intraday Surge - Markets Mojo
Insider Sell: Joy Liu Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Is Vertex Pharmaceuticals (VRTX) Still Attractively Priced After Its Multi Year Share Price Run? - simplywall.st
Global Orphan Drugs Market is Anticipated to Cross USD 350 Billion by 2032 | DelveInsight - Bolsamania
Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of - The Motley Fool
Director files Form 144 to sell shares (NASDAQ: VRTX) - Stock Titan
Teachers Retirement System of Kentucky Reduces Vertex Pharmaceuticals Stake - National Today
Teachers Retirement System of The State of Kentucky Decreases Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
William Blair Investment Management LLC Decreases Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
The Zacks Analyst Blog Highlights Broadcom, AT&T, Vertex and InterGroup - Zacks Investment Research
Top Research Reports for Broadcom, AT&T & Vertex Pharmaceuticals - Yahoo Finance
Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Vertex Pharmaceuticals Executive Sells Shares - TradingView
Finanzdaten der Vertex Pharmaceuticals Inc-Aktie (VRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):